Peritonectomy - Literature

Literature

1. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM. Surg Oncol Clin N Am. 2003 Jul;12(3):849-63
2. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Ann Surg Oncol. 2003 Mar;10(2):155-62
3. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Anticancer Res. 2003 May-Jun;23(3C):3019-27.
4. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW. Arch Surg. 2003 Jan;138(1):26-33.
5. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Anticancer Res. 2003 Mar-Apr;23(2B):1501-8.
6. Heated chemotherapy improves survival and quality of life in peritoneal carcinomatosis patients. Rollins G. Rep Med Guidel Outcomes Res. 2003 Feb 7;14(3):8-9. No Abstract Available.
7. Computed tomographic features of peritoneal carcinomatosis treated by intraperitoneal chemohyperthermia. Dromain C, Bisdorff A, Elias D, Antoun S, Boige V, Lasser P, Sigal R. J Comput Assist Tomogr. 2003 May-Jun;27(3):327-32.
8. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. J Clin Oncol 2003 Mar 1,21(5):762-4
9. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Ann Surg Oncol 2003; 10(3):210-212
10. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. Deraco M, Gronchi A, Mazzaferro V, Vaglini M et al. Tumori 2002 Sep-Oct; 88(5):370-5
11. Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. Sutton SW, Yancey LW, Chase VA et al. Perfusion 2002 Nov;17(6):441-6
12. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Panteix G, Beaujard A, Garbit F. et al. Anticancer Res 2002 Mar-Apr; 22(2B): 1329-36
13. Cytoreduction and hyperthermic-antiblastic peritoneal (HAPP) in peritoneal carcinomatosis [in italian] Vaira M, Scoderi S, Costamagna D et al. Minerva Chir 2002 Oct: 57(5): 597-605
14. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, et al. Eur J Surg Oncol 2002; 28(1),80-87
15. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Kunisaki C, Shimada H, Nomura M et al. Surgery 2002 May: 131(5): 521-8
16. Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis. Zanon C, Clara R, Bortolini M, Malossi A, Moscato R, Celoria P, de Andrea M, Rizzo M, Chiappino I, Grazia Sciuto M, Mussa A. Int J Hyperthermia. 2001 Sep-Oct;17(5):456-64.
17. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Int J Gynecol Cancer. 2001;11 Suppl 1:57-63.
18. Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis. Sugarbaker PH, Yonemura Y. Hepatogastroenterology 2001; Sept-Oct; 48(41): 1238-47
19. Rational and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Witkamp AJ, de Bree E, Van Goethem R et al. Cancer Treat Rev 2001 Dec: 27(6): 365-74
20. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Sugarbaker PH. Jpn J Clin Oncol 2001 Dec: 31(12): 573-83
21. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. M. Deraco, CR Rossi, et al and Maurizio Vaglini. Tumori 2001; 87(3):120-126
22. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. D. Elias, F. Blot, A. El Otmany et al. Cancer 2001; 92:71-76
23. ? Patients with pseudomixoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favourable prognosis than patients with peritoneal mucinous carcinomatosis. BM Ronnet, Hui Yan, RJ Kurman et al. Cancer 2001; 92:85-91
24. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. AJ Witkamp, E de Bree, MM Kaag et al. Eur J Canc 2001; 37(7), 979-984
25. 41,8°C whole body hyperthermia (WBH) combined with carboplatin in patients with advanced ovarian carcinoma. Dirk Jaeger, Akin Atmaca, Antje Neumann, Jan Unckell, Jacqueline Orth, Elke Jaeger, Alexander Knuth. Annals of Oncology, Vol 11, Suppl.4 October 2000, page 82
26. Whole body hyperthermia (WBH) at 41,8°C combined with ifosfamide (IFO) and carboplatin (CBDCA) in relapsed ovarian carcinoma pretreated with a platin-containing regimen. Yael Gruber, Susanna Hegewisch-Becker, Afsaneh Bakhshandeh-Bath, Harald Sommer, Rüdiger Hoffmann, Dieter K. Hossfeld. Annals of Oncology, Vol 11, Suppl.4 October 2000, page 85
27. Treatment of primary colon cancer with peritoneal carcinomatosis. Comparison of concomitant vs. delayed management. Sophie R. Pestieau, Paul H. Sugarbaker. Dis colon rectum, 2000; 10(43), 1341-1348
28. Results of treatment of 33 patients with peritoneal mesothelioma. G Sebbag, H Yan, BM Shmookler, D Chang, PH Sugarbaker. Br J Surg 2000; 87, 1587-1593
29. Hyperthermic intraperitoneal chemoperfusion in the treatment of locallt advanced intra-abdominal cancer. WP Ceele, U Hesse, B de Hemptinne and P Pattyn. Br J Surg 2000; 87, 1006-1015
30. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Zoetmulder FA, Kaag MM, Beijnemn JH. Eur J Surg Oncol 2000; 26(7):663-8
31. Peritoneal carcinomatosis from non gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. B Sadeghi, C Arvieux, O Glehen et al. Cancer 2000, 88:358-63
32. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? Shido A, Ohmura S, Yamamoto k, et al: World J Surg 2000;24, 507-511.
33. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate refression analysis. Hirose K, Katayama K, Iida A et al. Oncology 1999; 57(2):106-14
34. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: Phase I-II study. F Gilly, A Beaujard, O. Glehen et al. Anticancer Res; 1999, 19:2317-2322
35. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. D Tsiftisis, E de Bree, J Romanos et al. Arch Surg 1999; 134:545-549
36. Second-look surgery after cytoreduction an intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analisys of prognostic features. AG Portilla, PH Sugarbaker, D Chang. World J Surg 1999; 23:23-29
37. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adducts formation in patients and ovarian cancer lines. PJM van der Vaart, N van der Vange, FAN Zoetmulder et al.; Eur J Cancer 1998; Vol 34, 1, pp 148-154
38. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. DL Bartlett, JF Buell, SK Libutti, E Reed, KB Lee, WD Figg, DJ Venzon, HR Alexander. Cancer 1998; 83(6), 1251-1261
39. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Y Yonemura, T Fujiumura, G Nishimura et al. Surgery 1996; 119:437-44
40. Chemio-ipertermia perfusionale intra-peritoneale (CIPIP). Una nuova tecnica per il trattamento integrato delle neoplasie gastro-intestinali con interessamento peritoneale. M. Pace, A. Galli, D. Brugnola, A. Bellacci. J Chemother vol 8, suppl 3, 1996, pg 83
41. Isolated perfusion in oncological therapy. A. Galli, A. Bellacci, E. Macera Mascitelli, M. Pace. RBM 4/15, 223, 1993
42. Bonnefoi H,A'Hern RP,Fisher C,Macfarlane V,Barton D,Blake P,Shepherd JH,Gore ME:Natural history of stage IV epithelial ovarian cancer.J Clin Oncol 1999,17:767-775. Yancik R:Ovarian cancer.Age contrasts in incidence,histology,disease stage at diagnosis,and mortality.Cancer 1993, 71:517-523.
43. Stephens AD,Alderman R,Chang D,Edwards GD,Esquivel J,Sebbag G,Steves MA,Sugarbaker PH:Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using the Coliseum technique.Ann Surg Oncol 2000,6:790-796.
44. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993, 71:517-523
45. Abu-Rustum NR, Chi DS, Curtin JP: Epithelial ovarian cancer. Curr Probl Surg 1999, 36:7-53.
46. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J Clin Oncol 2002, 5:1248-1259
47. Kecmanovic DM, Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB: Cytoreductive surgery for ovarian cancer.Eur J Surg Oncol 2003, 29:315-320
48. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001, 87:120-126.
49. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003, 13:764-770.
50. Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, Pinedo HM: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992, 52:1252-1258.
51. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737-3743.
52. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 2000, 6:727-731.
53. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, Manns M, Klempnauer J: Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001, 27:286-290
54. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA: Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003, 10:155-162.
55. Sugarbaker PH: Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. In: Peritoneal carcinomatosis: drugs and diseases (Edited by: Sugarbaker P). Boston, Kluwer Academic Publishers 1996, 75-86.
56. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995, 221:29-42.
57. Sugarbaker PH: Management of peritoneal-surface malignancy: the surgeons role. Langenbecks Arch Surg 1999, 384:576-587.
58. Van der Burg MF: Advanced ovarian cancer. Curr Treat Options Oncol 2001, 2:109-118.
59. Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, Tang MQ, Liu Q: Effect of cytoreductive surgery on survival of patient with recurrent epithelial ovarian cancer.J Surg Oncol 2000, 75:24-30.
60. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.Cancer 1992, 70:2129-2136.
61. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophospahmide for stage III ovarian cancer. N Engl J Med 1996, 335:1950-1955
62. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001, 83:504-512
63. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001, 92:71-76.
64. Salom E, Almeida Z, Mirhashemi R: Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002, 14:519-527
65. Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K: Peritoneal cancer index:a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003, 29:69-73.
66. Gunderson LL., Sosin H: Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum: Clinicopathologic correlation and implications for adjuvant therapy. Cancer 34:1278-1292, 1974
67. Sugarbaker PH: Surgical management of locally recurrent and metastatic colorectal cancer. (In) Karakousis CP, Copeland EM and Bland QUI (eds); Atlas of Surgical Oncology. Saunders: Philadelphia pp 671-692, 1995 Sugarbaker PH, Hughes KA: Surgery for Colorectal Metastasis to Liver. (In) Wanebo H (ed); Colorectal Cancer Mosby-Year Book, Inc.: St. Louis, 405-413, 1993
68. Sugarbaker PH: Peritoneal Carcinomatosis: Principles of Management. Kluwer:Boston 1996
69. Sugarbaker PH: Peritoneal carcinomatosis from appendiceal cancer: A paradigm for treatment of abdomino-pelvic dissemination of gastrointestinal malignancy. Acta Chirurgica Austriaca 28:4-8, 1996
70. Sugarbaker PH: Peritonectomy procedures. (In) Sugarbaker PH (ed); Peritoneal Carcinomatosis: Principles of Management. Kluwer, Boston pp 235-262, 1996
71. Jacquet P, Vidal-Jove J, Zhu BW, Sugarbaker PH: Peritoneal carcinomatosis from intraabdominal malignancy: Natural history and new prospects for management. Acta Belgica Chirurgica 94:191-197, 1994
72. Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ Mullins RE, Hull WE, Oliff L, Schlag P: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 50:5790-5794, 1990
73. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Meyers CE: Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98:414-421, 1985
74. Sugarbaker PH, Averbach AM, Chang D: Adjuvant perioperative intraperitoneal chemotherapy for resectable gastric cancer: A call for a multi-institutional randomized trial. (In) Siewert JR, Roder JD (eds); Progress in Gastric Cancer Research, Monduzzi Editore: Bologna pp 1399-1405, 1997
75. Gough DB, Donahue JH, Schutt AJ, Ghonchoroff N, Goellner JR, Wilson TO, Naessens JM, O'Brien PC, van Heerden JA: Pseudomyxoma peritonei: Long-term survival with an aggressive regional approach. Ann Surg 219:112-119, 1994
76. Zoetmulder FAN, Sugarbaker PH: Patterns of failure after complete cytoreduction and early postoperative intraperitoneal chemotherapy. Eur J CA 32A(10):1727-1733, 1996
77. Jacquet P, Sugarbaker PH: Wound recurrence after laparoscopic colectomy for cancer: New rationale for intraoperative intraperitoneal chemotherapy. Surg Endosc 10:295-296,1996
78. Sugarbaker PH et al: Management of pseudomyxoma peritonei of appendiceal origin. Adv Surg 30:233-280, 1997
79. Archer A, Sugarbaker PH, Jelinek, J: Radiology of peritoneal carcinomatosis. (In) Sugarbaker PH (ed); Peritoneal Carcinomatosis: Principles of Management. Kluwer, Boston pp 263-288, 1996
80. Jacquet P, Jelinek J, Sugarbaker PH: Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am College Surg 181(6):530-538, 1995
81. Steller EP: Comparison of four scoring methods for an intraperitoneal immunotherapy model. Enhancement and Abrogation: Modifications of Host Immune Influence IL-2 and LAK Cell Immunotherapy (Ph.D. Thesis). Erasmus University Rotterdam, November 1988
82. Sugarbaker PH, Schellinx MET, Chang D, Koslowe P, von Meyerfeldt M: Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 20:585-592, 1996
83. Murio EJ, Sugarbaker PH: Gastrointestinal fistula following cytoreductive procedures for peritoneal carcinomatosis: Incidence and outcome. J Exp Clin Cancer Res 12:153-158,1993
84. Fernandez-Trio V, Sugarbaker PH: Diagnosis and management of postoperative gastrointestinal fistulas: A kinetic analysis. J Exp Clin Cancer Res 13:233-241,1994
85. Gilly FN, Sayag, AC, Carry PY, Braillon GG, James IM, Volloch AA, Panteix GG: Intraperitoneal chemo-hyperthermic (CHIP): A new therapy in the treatment of the peritoneal seedings. Int Surg 76:164-167, 1991
86. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi K, Arimizu N, Takamizawa H: Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 208(1):36-41, 1988
87. Yonemura Y et al: Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 119(4):437-444,1996
88. Fujimoto S et al: Positive results of combined therapy of surgery and intraperitoneal hyperthermia perfusion for far-advanced gastric cancer. Ann Surg 212(5):592-596, 1990
89. Averbach AM, Sugarbaker PH: Recurrent intraabdominal cancer with intestinal obstruction. Int Surg 80(2):141-146, 1995
90. Price B: Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997, 145:211-218.
91. Sridhar KS, et al.: New strategies are needed in diffuse malignant mesothelioma. Cancer 1992, 70:2969-2979.
92. Antman K, et al.: Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988, 6:147-153.
93. Asensio JA: Primary malignant peritoneal mesothelioma: a report of seven cases and a review of the literature. Arch Surg 1990,125:477-481.
94. Attanoos RL: Pathology of malignant mesothelioma. Histopathology 1997, 30:403-418.
95. Vidal-Jove J, et al.: A curative approach to abdominal mesothelioma: case report and review of the literature. Reg Cancer Treat 1991,3:269-274.
96. Wagner JC: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271.
97. Bocchetta M, et al.: Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000, 97:10214-10219.
98. Gilks B, et al.: Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 1988, 61:2019-2021.
99. Peterson JT: Non-asbestos related malignant mesothelioma. Cancer 1984, 54:951-960.
100. Roushdy-Hammady I, et al.: Genetic susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357:444-445.
101. Lerner HJ, et al.: Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981-1985.
102. Markman M: Intraperitoneal therapy in the management of peritoneal mesothelioma. J Infusional Chemother 1993, 3:50-52.
103. Zidar BL, et al.: Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer 1983, 52:1788-1791.
104. Biset D: The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol 1991, 3:315-317.
105. Sugarbaker PH, et al.: Early localized peritoneal mesothelioma as an incidental finding at laparoscopy: report of a case and implications regarding natural history of the disease. Cancer 2000, 89:1279-1284.
106. Markman M: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992, 118:547-550.
107. Neumann V: Peritoneal mesothelioma-incidence and etiology. Pathologie 1999, 20:169-176.
108. Eltabbakh GH, et al.: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999, 70:6-12.
109. Park BJ, et al.: Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999, 6:582-590.
110. Sugarbaker PH: Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute Experience. Semin Oncol 2002, 29:51-61.
111. Averbach AM: Peritoneal mesothelioma treatment approach based on natural history. Cancer Treat Res 1996, 81:193-211.
112. Sebbag G, et al.: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87:1-7.
113. Markman M, et al.: Phase 1 trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992, 10:1485-1491.
114. Markman M, et al.: Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. Ann Oncol 1994, 5:S55-S58.
115. Stephens AD, et al.: Morbidity and mortality of 200 treatments with cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999,6:790-796.
116. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following 'curative surgery' for adenocarcinoma of the rectum: clinicopathologic correlation and implications for adjuvant therapy.Cancer 1974;34:1278-92.
117. Sugarbaker PH. Management of peritoneal surface malignancy: appendix cancer and pseudomyxoma peritonei,colon cancer, gastric cancer, abdominopelvic sarcoma and primary peritoneal surface malignancy. In: Bland K,Daly JM, Karakousis CP, editors. Surgical Oncology Contemporary Principles and Practice. New York: McGraw-Hill 2001;1149-76.
118. Sugarbaker PH, Hughes KA. Surgery for colorectal metastasis to liver. In: Wanebo H, editor. Colorectal Cancer. St. Louis: Mosby Year Book. 1993;405-13.
119. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol1999;6:727-31
120. Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH. Pathobiology of peritoneal carcinomatosis from ovarian malignancy. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: Drugs and Diseases. Boston: Kluwer 1996;63-74.
121. Sugarbaker PH. Laser-mode electrosurgery. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer 1996;375-85.